Cresco Labs, Inc.

As of June 30, 2026, Cresco Labs, Inc. carries a market capitalization of 435.06M, placing it among publicly traded companies globally. Its enterprise value stands at 1.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cresco Labs, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cresco Labs, Inc. has 371.85M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.46, and the price-to-book ratio stands at 0.85.

As of June 30, 2026, Cresco Labs, Inc. trades at an EV/EBITDA multiple of 34.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.09B versus a market cap of 435.06M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cresco Labs, Inc. maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 224.80, indicating elevated leverage, while an interest coverage ratio of 0.37 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. posted a negative return on equity (ROE) of -25.13, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.73, reflecting losses generated across the asset base. The company generates approximately 318,652.77 in revenue per employee across its workforce of 2,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.25 indicates how many times Cresco Labs, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. recorded 12.66M in income tax expense. The company reported a pretax loss of -147.08M and -143.22M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Cresco Labs, Inc.'s stock has declined approximately 44.94% over the past 52 weeks. The 50-day moving average sits at 1.01, while the 200-day moving average is 1.23.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. generated 924.09M in revenue and converted that into -143.22M in net income, yielding earnings per share of -0.41. EBITDA reached 31.99M, while operating income came in at 88.68M.

As of June 30, 2026, Cresco Labs, Inc. holds 46.65M in cash and equivalents against 840.20M in total debt, resulting in a net debt position of 559.63M. Total book value stands at 509.06M, with working capital of 153.21M providing operational flexibility.

Cresco Labs, Inc. produced 61.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -55.00M in capital expenditures, free cash flow totaled 6.58M - equivalent to 0.02 per share.

Over the twelve months ended June 30, 2026, Cresco Labs, Inc. posted a gross margin of 49.92, reflecting its pricing power and cost economics. The operating margin of 9.60 and net profit margin of -15.50 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.45, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 28.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cresco Labs, Inc. shareholders.

Cresco Labs, Inc.'s most recent stock split took place on November 30, 2018 with a 81263:100 split ratio.

As of June 30, 2026, Cresco Labs, Inc. has an Altman Z-Score of -1.36, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.